Today, the Senate is expected to begin consideration of S. 1519, the FY 2018 National Defense Authorization Act (NDAA). As reported by the Senate Armed Services Committee, S. 1519 would have negative impacts on U.S. Department of Defense medical research programs. The Children’s Tumor Foundation has actively and continuously engaged for the past months in many avenues of bipartisan advocacy to nullify these specific provisions in the legislation, working with the Foundation’s Capitol Hill allies, the Defense Health Research Consortium, and other stakeholders to ensure no impact to the Department of Defense medical research programs. As a recognized leader in NF and medical research policy, and with an active presence on Capitol Hill for over two decades advocating for, protecting, and securing funding for NF research, the Children’s Tumor Foundation will continue to work tirelessly to defend these vital programs for our community. Watch this space for further updates, and progress, in the coming weeks and months.
Advocacy Update
